DOCSLIB.ORG

Download Chargemaster

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download Chargemaster SANTIAM HOSPITAL Providing price transpareny is important to us. Charge Master Report- Price List The listed prices do not take into account insurance coverge or out of pocket expenses Charge Code Description Departme Rev Proc Rate Please contact us for price estimate clarification nt Code Code AMBULANCE SERVICE ALS - EMERGENT AMB AMBULANCE 540 A0427 1,503.50 AMBULANCE SERVICE ALS 1 AMB AMBULANCE 540 A0426 949.50 AMBULANCE SERVICE ALS 2 AMB AMBULANCE 540 A0433 2,176.00 AMBULANCE SERVICE BLS - EMERGENT AMB AMBULANCE 540 A0429 1,266.00 AMBULANCE SERVICE BLS AMB AMBULANCE 540 A0428 790.00 AMBULANCE GROUND MILEAGE, ALS AMB AMBULANCE 540 A0425 28.00 SPECIAL CARE TRANSPORT AMB AMBULANCE 540 A0434 2,571.00 31500 INTUBATION EMERG PR ANES SURGERY 963 31500 425.00 VENIPUNCTURE BY HC PRO FE ANES SURGERY 963 36410 28.50 INSERT NON TUNNEL CATH ANES SURGERY 963 36556 295.50 62270 SPINAL PUNCTURE DX ANES SURGERY 963 62270 235.00 FEMORAL NERVE BLOCK PF ANES SURGERY 963 64447 1,447.00 PERIPHERAL NERVE BLOCK PF ANES SURGERY 963 64450 136.50 64415 ANES SINGLE NERVE BLOCK INJECTION ANES SURGERY 963 64415 198.00 RBC'S/ LEUKO DEPLETED BB LAB 390 J3490 485.50 FRESH FROZEN PLASMA BB LAB 390 J3490 250.00 PLATELETS-PHERESIS BB LAB 390 J3490 1,274.00 RBC, IRRADIATED, LEUKO BB LAB 390 J3490 551.00 BLOOD PRODUCT (CYRO) CHARGE BB LAB 390 J3490 675.50 PLATELET IRRADIATED BB LAB 390 J3490 1,500.50 ABG - COMPLETE CR CARDOPULMONARY 301 82803 177.50 ABG, ARTERIAL PUNCTURE CR CARDOPULMONARY 300 36600 34.50 ABG, O2 SAT CR CARDOPULMONARY 301 82810 22.50 ABG, PCO2 CR CARDOPULMONARY 301 82803 56.50 ABG, PH CR CARDOPULMONARY 301 82800 44.00 ABG, PO2 CR CARDOPULMONARY 301 82803 99.00 BALLARD SWIVEL CR CARDOPULMONARY 410 15.50 BI PAP CR CARDOPULMONARY 410 94002 1,472.50 BI PAP/ PER SUB DAY CR CARDOPULMONARY 410 94003 1,472.50 CARDIO RESUSCITATION CR CARDOPULMONARY 410 159.50 CONT NEB PER HR/MX/DLY CR CARDOPULMONARY 410 94640 595.00 ENDOTR SUCT DAILY CHARGE CR CARDOPULMONARY 410 67.50 ENDOTRACHEAL INTUBATION CR CARDOPULMONARY 410 31500 570.50 INCENTIVE SPIRO THERAPY CR CARDOPULMONARY 410 94799 436.00 !1 MECH VENT INITIAL DAY CR CARDOPULMONARY 410 94002 1,472.50 MECH VENT/SUB CR CARDOPULMONARY 410 94003 1,472.50 NASOTRACHEAL SUCTIONING CR CARDOPULMONARY 410 31720 596.00 OXYGEN ANALYZER--CONT CR CARDOPULMONARY 410 40.50 P D & P SUBSEQUENT CR CARDOPULMONARY 410 94668 336.00 PEP THERAPY CR CARDOPULMONARY 410 94667 336.00 RESP MDI CR CARDOPULMONARY 410 94664 596.00 RESP NEBS CR CARDOPULMONARY 410 94664 596.00 TECH ASST SURG C SECTION CR CARDOPULMONARY 410 76.50 TRACHEAL LAVAGE & SUCTION CR CARDOPULMONARY 410 64.00 VEST THERAPY CR CARDOPULMONARY 410 94667 336.00 VEST THERAPY SUBQ CR CARDOPULMONARY 410 94668 336.00 CARBON MONOXIDE CR CARDOPULMONARY 460 82375 61.50 END TIDAL CO2 CR CARDOPULMONARY 460 94770 747.00 HOME OXYGEN EVALUATION CR CARDOPULMONARY 410 94618 315.00 METH HGB CR CARDOPULMONARY 460 83050 61.50 NOCTURNAL OXIMETRY I NPT CR CARDOPULMONARY 460 94762 409.00 OXIMETRY, PER HR CR CARDOPULMONARY 460 39.50 SPIROMETRY, BASIC CR CARDOPULMONARY 460 94010 409.00 PULMONARY FUNCTION TEST (PFT) CR CARDOPULMONARY 460 94060 747.00 EVENT MONITOR RECORDING CR CARDOPULMONARY 480 93270 121.00 EVENT MONITOR ANALYSIS CR CARDOPULMONARY 480 93271 368.00 EKG PROCEDURE CR CARDOPULMONARY 730 93005 168.00 RHYTHM ECG STRIP/1 MINUTE CR CARDOPULMONARY 730 93041 168.00 HOLTER UP TO 48HRS WITH SCAN & REPORT CR CARDOPULMONARY 731 93226 315.00 HOLTER MONITOR UP TO 48 HR RECORDING CR CARDOPULMONARY 731 93225 315.00 EXERCISE OXIMETRY CR CARDOPULMONARY 460 94761 72.00 PULSE OXIMETRY CR CARDOPULMONARY 460 94760 42.00 LDR NEONATE RESUSCITATION CR CARDOPULMONARY 410 99465 157.00 SPUTUM INDUCTION CR CARDOPULMONARY 410 89220 64.00 CONTINUOUS NEB (INITIAL) CR CARDOPULMONARY 410 94644 336.00 CONTINUOUS NEB EACH ADDL HOUR CR CARDOPULMONARY 410 94645 48.00 CPAP INITIATION AND MANAGEMENT CR CARDOPULMONARY 410 94660 596.00 LDR - ATTEND DELIVERY (REQUESTED BY PHY) CR CARDOPULMONARY 410 99464 225.00 TRANSTRACHEAL PERCUTANEOUS VENTILATION CR CARDOPULMONARY 410 31730 4,230.00 ABG - BICARB CR CARDOPULMONARY 301 82374 29.50 IRHYTHM ECG HOOK UP / RECORDING CR CARDOPULMONARY 730 0296T 355.00 ABG, SAMPLE KIT CR CARDOPULMONARY 270 31.50 AIRWAY, NASAL\ORAL CR CARDOPULMONARY 270 19.50 AIRWAY, ORAL CR CARDOPULMONARY 270 22.50 AMBU BAG CR CARDOPULMONARY 270 29.50 !2 AMBU BAG DISPOSIBLE CR CARDOPULMONARY 270 95.50 AMBU BAG MASK- ALL SIZES CR CARDOPULMONARY 270 49.50 BALLARD SUCT. CATH CR CARDOPULMONARY 270 81.00 BI PAP CIRCUIT CR CARDOPULMONARY 270 36.50 BVM, DISPOSABLE NEO-NATAL CR CARDOPULMONARY 270 78.00 CIRCUIT, MECH VENT CR CARDOPULMONARY 270 125.50 CONNECTING TUBE, OXYGEN CR CARDOPULMONARY 270 17.00 CONNECTING TUBE-10FT CR CARDOPULMONARY 270 28.00 CONNECTING TUBE-25FT CR CARDOPULMONARY 270 40.50 CONT. NEB SETUP CR CARDOPULMONARY 270 127.50 ENVIRONMENT TENT/SET-UP CR CARDOPULMONARY 270 74.00 H2O STER/DIST ALL SIZES/E CR CARDOPULMONARY 270 21.50 HUMIDVENT CR CARDOPULMONARY 270 22.50 HYPERTONIC SALINE 15ML/3% CR CARDOPULMONARY 270 21.50 INTUBATION TUBE CR CARDOPULMONARY 270 36.50 MASK, AEROSOL CR CARDOPULMONARY 270 29.50 MASK, FACE TENT CR CARDOPULMONARY 270 31.50 MASK, NONREBREATHER CR CARDOPULMONARY 270 31.50 MASK, PEDIATRIC CR CARDOPULMONARY 270 29.50 MASK, SIMPLE OXYGEN CR CARDOPULMONARY 270 29.50 MASK, TOTAL FACE BIPAP CR CARDOPULMONARY 270 174.00 NEOPUFF CIRCUIT CR CARDOPULMONARY 270 24.50 OXIMETER PROBE NEONATAL CR CARDOPULMONARY 270 132.00 OXIMETER PROBE PED CR CARDOPULMONARY 270 101.00 OXYMIZER CR CARDOPULMONARY 270 52.00 PEF METER CR CARDOPULMONARY 270 101.00 SALINE ALL SIZES CR CARDOPULMONARY 270 21.50 TRACH COLLAR CR CARDOPULMONARY 270 36.50 VEST FULL CR CARDOPULMONARY 270 273.50 VEST WRAP CR CARDOPULMONARY 270 187.50 THERAPEUTIC PROCEDURE STRENGTH / ENDURAN CR CARDOPULMONARY 410 G0237 102.00 VEST HFCWC CR CARDOPULMONARY 410 94669 596.00 IRHYTHM ECG REVIEW AND INTERPRETATION CRDP CARDOPULMONARY 960 0298T 50.00 TRAY ARTHROGRAM CS SUPPLIES 270 9.00 2 X 2 DRESSING CS SUPPLIES 270 12.00 4 X 4 4 PLY EACH 2/PKG CS SUPPLIES 270 13.00 4 X 4 STERILE DRESSING/10 CS SUPPLIES 270 21.50 ABD BINDER, DALE 62x75 CS SUPPLIES 270 149.50 ACE WRAP ALL SIZES CS SUPPLIES 270 22.50 AIR WALKER (REBOUND) LOW CS SUPPLIES 270 122.50 BINDER, ABDOMINAL SURGICA CS SUPPLIES 270 149.50 !3 CATH, FOLEY ALL SIZES CS SUPPLIES 270 61.50 CATH, LEG BAG CS SUPPLIES 270 19.50 CATH, MINI CS SUPPLIES 270 15.50 CATH, SECURE FOR LEG BAG CS SUPPLIES 270 10.00 CERVICAL, COLLAR FOAM CS SUPPLIES 270 42.00 CERVICAL, COLLAR STIFF CS SUPPLIES 270 101.00 COLOSTOMY BAG CS SUPPLIES 270 40.50 DRESSING CHANGE - LARGE CS SUPPLIES 270 46.50 DRESSING CHANGE - MEDIUM CS SUPPLIES 270 22.50 DRESSING CHANGE - SMALL CS SUPPLIES 270 12.00 DRESSING, BIOCLUSIVE 4X5 CS SUPPLIES 270 18.00 EYE PATCH, EA CS SUPPLIES 270 13.00 GLOVE, STER. MICROTOUCH CS SUPPLIES 270 13.00 IMMOBILIZER BOOT 79-95415 CS SUPPLIES 270 85.50 KCI PROVENA DISP VAC CS SUPPLIES 270 1,010.50 SALINE 1000CC CS SUPPLIES 270 19.50 SHOTS BIOCLUSIVE 4X5 CS SUPPLIES 270 18.00 SHOTS FOLEY CATH CS SUPPLIES 270 61.50 SHOTS NEDDLE HUEBER CS SUPPLIES 270 17.00 SHOTS SKIN PREP NO-STING CS SUPPLIES 270 8.00 SHOTS STATLOCK PICC SECU CS SUPPLIES 360 44.00 SHOTS SURG SCRUB SPONGE CS SUPPLIES 270 17.00 SHOTS SUTURE REMOVAL KIT CS SUPPLIES 270 12.00 SLING CS SUPPLIES 270 49.50 SPLINT, ANKLE AIR CS SUPPLIES 270 189.00 SPLINT, ANKLE ELAS WRAP CS SUPPLIES 270 31.50 SPLINT, FINGER-ALUM CS SUPPLIES 270 13.00 SPLINT, FINGER-FROG CS SUPPLIES 270 18.00 SPLINT, FOREARM #12-01T00 CS SUPPLIES 270 42.00 SPLINT, LONG ARM CS SUPPLIES 270 128.50 SPLINT, LONG LEG CS SUPPLIES 270 155.50 SPLINT, POSTERIOR CS SUPPLIES 270 82.50 SPLINT, SHORT ARM CS SUPPLIES 270 98.00 SPLINT, SHORT LEG CS SUPPLIES 270 136.50 SPLINT, SUGAR TONG SH ARM CS SUPPLIES 270 54.50 SUCTION CANNISTER CS SUPPLIES 270 19.50 SUCTION,TUBING 10' CS SUPPLIES 270 13.00 SYRINGE ALL CS SUPPLIES 270 13.00 TED HOSE KNEE LGTH/PR CS SUPPLIES 270 58.00 TRAY, BREAST LOC CS SUPPLIES 270 58.00 TUBE, NASAL GASTRIC CS SUPPLIES 270 19.50 UNNABOOT CS SUPPLIES 270 35.50 !4 CATH, INDWELLING TRAY CS SUPPLIES 270 A4312 70.00 SPLINT CS SUPPLIES 270 A4570 28.00 SPLINT, FINGER-VELCRO #39 CS SUPPLIES 270 A4570 37.50 SPLINT, FORE & WRIST w/VE CS SUPPLIES 270 A4570 74.00 SMALL JNT IMPLANT CS SUPPLIES 278 C1776 1,229.00 CRUTCHES COMPLETE CS SUPPLIES 270 151.00 BREAST PUMP KIT CS SUPPLIES 270 E0602 75.00 BREAST PUMP, MEDELA ELEC. CS SUPPLIES 271 E0603 290.00 SPLINT, KNEE UNIVERSAL CS SUPPLIES 270 64.50 SPLINT ANKLE STABILING SU CS SUPPLIES 270 71.00 CAST SHOE/KOOL KOLOR 1487 CS SUPPLIES 274 70.00 SHOE, MED/SURG POST-OP CS SUPPLIES 274 70.00 SHOULDER ABDUCTION FIG 8 CS SUPPLIES 270 231.00 SPLINT, SHOULDER IMMOB CH CS SUPPLIES 270 141.50 SPLINT, 10 LACE-UP WRIST CS SUPPLIES 270 44.50 SPLINT, WRIST COCK-UP CS SUPPLIES 270 76.50 SPLINT, WRIST-ELASTIC CS SUPPLIES 270 37.50 WRIST SUPPORT ELASTIC CS SUPPLIES 270 32.50 WRIST/ FOREAREM ELASTIC CS SUPPLIES 270 25.00 SPLINT, THUMB SPICA BRACE CS SUPPLIES 270 44.00 SPLINT, ANKLE 79-81197 CS SUPPLIES 270 71.00 SPLINT, ANKLE SUPPORT CS SUPPLIES 270 82.50 MAXTRAX AIR WALKER #79-95 CS SUPPLIES 270 99.00 INTRAOCULAR, CILCO-UV LEN CS SUPPLIES 276 V2632 2,325.00 .45NS 1000ML CS SUPPLIES 260 8.00 .45NS 500ML CS SUPPLIES 260 7.00 .9NS 1000ML CS SUPPLIES 260 7.00 .9NS 100ML CS SUPPLIES 260 6.00 .9NS 100ML ADVANTAGE CS SUPPLIES 260 12.00 .9NS 250ML CS SUPPLIES 260 6.00 .9NS 500ML CS SUPPLIES 260 6.00 .9NS 50ML CS SUPPLIES 260 6.00 .9NS 50ML ADVANTAGE CS SUPPLIES 260 12.00 .9NS IRRIGATION 3000ML CS SUPPLIES 260 27.00 .9NS IRRIGATION BTL 1000ML CS SUPPLIES 260 8.00 20MEQ KCL
Load more

Recommended publications
  • Oral Presentations September 23Rd - Rooms 1,2 and 3
    Oral Presentations September 23rd - Rooms 1,2 and 3 Presentation Date Abstract Authors Presenter´s name - Theme Title Code indicated by the author 18498 Thomas Smits; Femke Gresnigt; Thomas Smits Clinical Toxicology/drugs of PERFORMANCE OF AN IMMUNOASSAY Eric Franssen; Milly Attema-de abuse METHOD FOR GAMMA-HYDROXYBUTYRIC Jonge ACID (GHB) IN PATIENTS PRESENTED AT THE EMERGENCY DEPARTMENT, A PROSPECTIVE STUDY 18499 Thomas Smits; Femke Gresnigt; Thomas Smits Clinical Toxicology/drugs of DO WE NEED POINT-OF-CARE TESTING OF Milly Attema-de Jonge; Eric abuse GAMMA-HYDROXYBUTYRIC ACID (GHB) AT Fransse THE EMERGENCY DEPARTMENT? September 23 18730 Lilian H.J. Richter; Julia Menges; Lea Wagmann Clinical Toxicology/drugs of NEW PSYCHOACTIVE SUBSTANCES: Lea Wagmann; Simon D. Brandt; abuse METABOLIC FATE, ISOZYME-MAPPING, 13:30 - 14:45 Folker Westphal; Veit Flockerzi; AND PLASMA PROTEIN BINDING OF 5-APB- ROOM 1 Markus R. Meyer NBOME, 2C-B-FLY-NB2ETO5CL, AND 2C-B- FLY-NBOME 18985 Annelies Cannaert; Marie Annelies Cannaert Clinical Toxicology/drugs of HIDE AND SEEK: OVERCOMING THE Deventer; Melissa Fogarty; abuse MASKING EFFECT OF OPIOID Amanda L.A. Mohr; Christophe P. ANTAGONISTS IN ACTIVITY-BASED Stove SCREENING TESTS 18740 Souleiman El Balkhi ; Roland Souleiman El Balkhi Clinical Toxicology/drugs of METABOLIC INTERACTIONS BETWEEN Lawson; Franck Saint-Marcoux abuse OXYCODONE, BENZODIAZEPINES OR DESIGNER BENZODIAZEPINES PLAY AN IMPORTANT ROLE IN OXYCODONE INTOXICATIONS 19050 Brenda de Winter F de Velde; MN Brenda de Winter Anti-infective drugs POPULATION
    [Show full text]
  • The Femoral Nerve Block Characteristics Using Ropivacaine 0.2% Alone, with Epinephrine, Or with Lidocaine and Epinephrine
    SCIENTIFIC ARTICLES THE FEMORAL NERVE BLOCK CHARACTERISTICS USING ROPIVACAINE 0.2% ALONE, WITH EPINEPHRINE, OR WITH LIDOCAINE AND EPINEPHRINE A.M. TAHA1,2 AND A.M. ABD-ELmaKSOUD31* Keywords: anesthetic techniques, regional, femoral; anaesthetics local, ropivacaine; equipment, ultrasound machines. Abstract Background: The objective of this study was to evaluate the femoral nerve block characteristics (onset, success rate and duration) using ropivacaine 0.2% alone; with epinephrine, or with lidocaine and epinephrine compared with that using ropivacaine 0.5%. Methods: Ninety six patients were included in this prospective controlled double blind study and were randomly allocated into four equal groups (n=24). All the patients received ultrasound guided femoral nerve block using 15 ml of either ropivacaine 0.5% (group 1), ropivacaine 0.2% (group 2), ropivacaine 0.2% with epinephrine (group 3) and ropivacaine 0.2% with lidocaine and epinephrine (group 4). The block onset, success rate and duration were recorded. Results: The motor onset was significantly delayed in group 2 (compared with the other three groups) and in group 3 (compared with group 4). However, the block success rate and duration were comparable in the four groups. Conclusion: In femoral nerve block, ropivacaine 0.2% may have a comparable success rate and duration to ropivacaine 0.5% but with a remarkably delayed motor onset that may be improved by adding epinephrine. Addition of lidocaine may further accelerate the motor onset. Introduction The femoral nerve block (FNB) is a commonly indicated block, and ropivacaine is a widely used long acting local anesthetic (LA)1,2. Peripheral nerve blocks can provide excellent anesthesia and postoperative analgesia 3,4.
    [Show full text]
  • PPE Requirements Hazardous Drug Handling
    This document’s purpose is only to provide general guidance. It is not a definitive interpretation for how to comply with DOSH requirements. Consult the actual NIOSH hazardous drugs list and program regulations in entirety to understand all specific compliance requirements. Minimum PPE Required Minimum PPE Required Universal (Green) - handling and disposed of using normal precautions. PPE Requirements High (Red) - double gloves, gown, eye and face protection in Low (Yellow) - handle at all times with gloves and appropriate engineering Hazardous Drug Handling addition to any necessary controls. engineering controls. Moderate (Orange) -handle at all times with gloves, gown, eye and face protection (with splash potential) and appropirate engineering controls. Tablet Open Capsule Handling only - Contained Crush/Split No alteration Crush/Split Dispensed/Common Drug Name Other Drug Name Additional Information (Formulation) and (NIOSH CATEGORY #) Minimum PPE Minimum PPE Minimum PPE Minimum PPE Required required required required abacavir (susp) (2) ziagen/epzicom/trizivir Low abacavir (tablet) (2) ziagen/epzicom/trizivir Universal Low Moderate acitretin (capsule) (3) soriatane Universal Moderate anastrazole (tablet) (1) arimidex Low Moderate High android (capsule) (3) methyltestosterone Universal Moderate apomorphine (inj sq) (2) apomorphine Moderate arthotec/cytotec (tablet) (3) diclofenac/misoprostol Universal Low Moderate astagraf XL (capsule) (2) tacrolimus Universal do not open avordart (capsule) (3) dutasteride Universal Moderate azathioprine
    [Show full text]
  • Management of Status Epilepticus
    Published online: 2019-11-21 THIEME Review Article 267 Management of Status Epilepticus Ritesh Lamsal1 Navindra R. Bista1 1Department of Anaesthesiology, Tribhuvan University Teaching Address for correspondence Ritesh Lamsal, MD, DM, Department Hospital, Institute of Medicine, Tribhuvan University, Nepal of Anaesthesiology, Tribhuvan University Teaching Hospital, Institute of Medicine, Tribhuvan University,Kathmandu, Nepal (e-mail: [email protected]). J Neuroanaesthesiol Crit Care 2019;6:267–274 Abstract Status epilepticus (SE) is a life-threatening neurologic condition that requires imme- diate assessment and intervention. Over the past few decades, the duration of seizure Keywords required to define status epilepticus has shortened, reflecting the need to start thera- ► convulsive status py without the slightest delay. The focus of this review is on the management of con- epilepticus vulsive and nonconvulsive status epilepticus in critically ill patients. Initial treatment ► neurocritical care of both forms of status epilepticus includes immediate assessment and stabilization, ► nonconvulsive status and administration of rapidly acting benzodiazepine therapy followed by nonbenzodi- epilepticus azepine antiepileptic drug. Refractory and super-refractory status epilepticus (RSE and ► refractory status SRSE) pose a lot of therapeutic problems, necessitating the administration of contin- epilepticus uous infusion of high doses of anesthetic agents, and carry a high risk of debilitating ► status epilepticus morbidity as well as mortality. ► super-refractory sta- tus epilepticus Introduction occur after 30 minutes of seizure activity. However, this working definition did not indicate the need to immediately Status epilepticus (SE) is a medical and neurologic emergency commence treatment and that permanent neuronal injury that requires immediate evaluation and treatment. It is associat- could occur by the time a clinical diagnosis of SE was made.
    [Show full text]
  • Ultrasound Guided Femoral Nerve Block
    Ultrasound Guided Femoral Nerve Block Michael Blaivas, MD, FACEP, FAIUM Clinical Professor of Medicine University of South Carolina School of Medicine AIUM, Third Vice President President, Society for Ultrasound Medical Education Past President, WINFOCUS Editor, Critical Ultrasound Journal Sub-specialty Editor, Journal of Ultrasound in Medicine Emergency Medicine Atlanta, Georgia [email protected] Disclosures • No relevant disclosures to lecture Objectives • Discuss anatomy of femoral nerve • Discuss uses of femoral nerve block classically and 3-in-1 variant • Discuss technique of femoral nerve blockade under ultrasound • Discuss pitfalls and potential errors Femoral Nerve Block Advantages • Many uses of regional nerve blocks • Avoid narcotics and their complications • Allow for longer term pain control • Can be used in patients unfit for sedation – Poor lung health – Hypotensive – Narcotic dependence or sensitivity Femoral Nerve Blocks • Wide variety of potential indications for a femoral nerve block – Hip fracture – Knee dislocation – Femoral fracture – Laceration repair – Burn – Etc. Nerve Blocks in Community vs. Academic Setting • Weekend stays • Night time admissions • Time to get consult and clear • Referral and admission patters • All of these factors can lead to patients spending considerable time prior to OR • Procedural sedation vs. block Femoral Nerve Blocks • Several basic principles with US also • Specialized needles +/- • No nerve stimulator • Can see nerve directly and inject directly around target nerve or nerves • Only
    [Show full text]
  • Anthem Blue Cross Drug Formulary
    Erythromycin/Sulfisoxazole (generic) INTRODUCTION Penicillins ...................................................................... Anthem Blue Cross uses a formulary Amoxicillin (generic) (preferred list of drugs) to help your doctor Amoxicillin/Clavulanate (generic/Augmentin make prescribing decisions. This list of drugs chew/XR) is updated quarterly, by a committee Ampicillin (generic) consisting of doctors and pharmacists, so that Dicloxacillin (generic) the list includes drugs that are safe and Penicillin (generic) effective in the treatment of diseases. If you Quinolones ..................................................................... have any questions about the accessibility of Ciprofloxacin/XR (generic) your medication, please call the phone number Levofloxacin (Levaquin) listed on the back of your Anthem Blue Cross Sulfonamides ................................................................ member identification card. Erythromycin/Sulfisoxazole (generic) In most cases, if your physician has Sulfamethoxazole/Trimethoprim (generic) determined that it is medically necessary for Sulfisoxazole (generic) you to receive a brand name drug or a drug Tetracyclines .................................................................. that is not on our list, your physician may Doxycycline hyclate (generic) indicate “Dispense as Written” or “Do Not Minocycline (generic) Substitute” on your prescription to ensure Tetracycline (generic) access to the medication through our network ANTIFUNGAL AGENTS (ORAL) _________________ of community
    [Show full text]
  • EAU-EANM-ESUR-ESTRO-SIOG Guidelines on Prostate Cancer 2019
    EAU - EANM - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer N. Mottet (Chair), R.C.N. van den Bergh, E. Briers (Patient Representative), P. Cornford (Vice-chair), M. De Santis, S. Fanti, S. Gillessen, J. Grummet, A.M. Henry, T.B. Lam, M.D. Mason, T.H. van der Kwast, H.G. van der Poel, O. Rouvière, D. Tilki, T. Wiegel Guidelines Associates: T. Van den Broeck, M. Cumberbatch, N. Fossati, T. Gross, M. Lardas, M. Liew, L. Moris, I.G. Schoots, P-P.M. Willemse © European Association of Urology 2019 TABLE OF CONTENTS PAGE 1. INTRODUCTION 9 1.1 Aims and scope 9 1.2 Panel composition 9 1.2.1 Acknowledgement 9 1.3 Available publications 9 1.4 Publication history and summary of changes 9 1.4.1 Publication history 9 1.4.2 Summary of changes 9 2. METHODS 12 2.1 Data identification 12 2.2 Review 13 2.3 Future goals 13 3. EPIDEMIOLOGY AND AETIOLOGY 13 3.1 Epidemiology 13 3.2 Aetiology 14 3.2.1 Family history / genetics 14 3.2.2 Risk factors 14 3.2.2.1 Metabolic syndrome 14 3.2.2.1.1 Diabetes/metformin 14 3.2.2.1.2 Cholesterol/statins 14 3.2.2.1.3 Obesity 14 3.2.2.2 Dietary factors 14 3.2.2.3 Hormonally active medication 15 3.2.2.3.1 5-alpha-reductase inhibitors 15 3.2.2.3.2 Testosterone 15 3.2.2.4 Other potential risk factors 15 3.2.3 Summary of evidence and guidelines for epidemiology and aetiology 16 4.
    [Show full text]
  • CEREBYX® (Fosphenytoin Sodium Injection)
    NDA 020450 Cerebyx (fosphenytoin sodium) Injection FDA Approved Labeling Text dated 10/2011 Page 1 of 22 CEREBYX® (Fosphenytoin Sodium Injection) WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH RAPID INFUSION RATES The rate of intravenous CEREBYX administration should not exceed 150 mg phenytoin sodium equivalents (PE) per minute because of the risk of severe hypotension and cardiac arrhythmias. Careful cardiac monitoring is needed during and after administering intravenous CEREBYX. Although the risk of cardiovascular toxicity increases with infusion rates above the recommended infusion rate, these events have also been reported at or below the recommended infusion rate. Reduction in rate of administration or discontinuation of dosing may be needed (see WARNINGS and DOSAGE AND ADMINISTRATION). DESCRIPTION CEREBYX® (fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. 1.5 mg of fosphenytoin sodium is equivalent to 1 mg phenytoin sodium, and is referred to as 1 mg phenytoin sodium equivalents (PE). The amount and concentration of fosphenytoin is always expressed in terms of mg PE. CEREBYX is marketed in 2 mL vials containing a total of 100 mg PE and 10 mL vials containing a total of 500 mg PE. The concentration of each vial is 50 mg PE/mL. CEREBYX is supplied in vials as a ready-mixed solution in Water for Injection, USP, and Tromethamine, USP (TRIS), buffer adjusted to pH 8.6 to 9.0 with either Hydrochloric Acid, NF, or Sodium Hydroxide, NF. CEREBYX is a clear, colorless to pale yellow, sterile solution. The chemical name of fosphenytoin is 5,5-diphenyl-3-[(phosphonooxy)methyl]-2,4­ imidazolidinedione disodium salt.
    [Show full text]
  • TRACON Pharmaceuticals, Inc. IND 132664 5.3.3.2 Clinical Study
    TRACON Pharmaceuticals, Inc. IND 132664 5.3.3.2 Clinical Study Protocol 253PC101 Protocol Amendment #4 Dated 30May2019 IN CASE OF EMERGENCY Table 1: Emergency Contact Information Role in Study Name Address and Telephone number Primary Medical Monitor James Freddo, MD 4350 La Jolla Village Drive, Suite 800 San Diego, CA 92122 Mobile Phone: 1.858.472.2330 Facsimile: 1.858.550.0786 Email: [email protected] Secondary Medical Monitor Charles Theuer, MD, PhD 4350 La Jolla Village Drive, Suite 800 San Diego, CA 92122 Office: 1.858.550.0780 x233 Mobile Phone: 1.858.344.9400 Email: [email protected] Confidential Page 2 of 102 TRACON Pharmaceuticals, Inc. IND 132664 5.3.3.2 Clinical Study Protocol 253PC101 Protocol Amendment #4 Dated 30May2019 1. SYNOPSIS Name of Sponsor/Company: TRACON Pharmaceuticals, Inc. Name of Investigational Product: TRC253 Name of Active Ingredient: TRC253-HCl Title of Study: AN OPEN-LABEL PHASE 1/2A STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY EFFICACY OF TRC253, AN ANDROGEN RECEPTOR ANTAGONIST, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Study center(s): 6 centers in Part 1, and approximately 20 centers in Part 2, in the United States Studied period: Phase of development: 1/2A Date first patient enrolled: May 2017 Date of determination of recommended phase 2 dose (RP2D): July 2018 Estimated date last patient enrolled: April 2021 Estimated date last patient completed: October 2021 Rationale: TRC253 is a high-affinity, small molecule antagonist of the androgen receptor (AR) with inhibitory activity against wild type AR and specific mutated variants of AR.
    [Show full text]
  • Calcium Channel Blocker As a Drug Candidate for the Treatment of Generalised Epilepsies
    UNIVERSITAT DE BARCELONA Faculty of Pharmacy and Food Sciences Calcium channel blocker as a drug candidate for the treatment of generalised epilepsies Final degree project Author: Janire Sanz Sevilla Bachelor's degree in Pharmacy Primary field: Organic Chemistry, Pharmacology and Therapeutics Secondary field: Physiology, Pathophysiology and Molecular Biology March 2019 This work is licensed under a Creative Commons license ABBREVIATIONS AED antiepileptic drug AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ANNA-1 antineuronal nuclear antibody 1 BBB blood-brain barrier Bn benzyl BnBr benzyl bromide BnNCO benzyl isocyanate Boc tert-butoxycarbonyl Bu4NBr tetrabutylammonium bromide Ca+2 calcium ion CACNA1 calcium channel voltage-dependent gene cAMP cyclic adenosine monophosphate CCB calcium channel blocker cGMP cyclic guanosine monophosphate CH3CN acetonitrile Cl- chlorine ion Cmax maximum concentration CMV cytomegalovirus CTScan computed axial tomography DCM dichloromethane DIPEA N,N-diisopropylethylamine DMF dimethylformamide DMPK drug metabolism and pharmacokinetics DNET dysembryoplastic neuroepithelial tumours EEG electroencephalogram EPSP excitatory post-synaptic potential FDA food and drug administration Fe iron FLIPR fluorescence imaging plate reader fMRI functional magnetic resonance imaging GABA γ-amino-α-hydroxybutyric acid GAD65 glutamic acid decarboxylase 65 GAERS generalised absence epilepsy rat of Strasbourg GluR5 kainate receptor GTC generalised tonic-clonic H+ hydrogen ion H2 hydrogen H2O dihydrogen dioxide (water)
    [Show full text]
  • Mechanisms of Action of Antiepileptic Drugs
    Review Mechanisms of action of antiepileptic drugs Epilepsy affects up to 1% of the general population and causes substantial disability. The management of seizures in patients with epilepsy relies heavily on antiepileptic drugs (AEDs). Phenobarbital, phenytoin, carbamazepine and valproic acid have been the primary medications used to treat epilepsy for several decades. Since 1993 several AEDs have been approved by the US FDA for use in epilepsy. The choice of the AED is based primarily on the seizure type, spectrum of clinical activity, side effect profile and patient characteristics such as age, comorbidities and concurrent medical treatments. Those AEDs with broad- spectrum activity are often found to exert an action at more than one molecular target. This article will review the proposed mechanisms of action of marketed AEDs in the US and discuss the future of AEDs in development. 1 KEYWORDS: AEDs anticonvulsant drugs antiepileptic drugs epilepsy Aaron M Cook mechanism of action seizures & Meriem K Bensalem-Owen† The therapeutic armamentarium for the treat- patients with refractory seizures. The aim of this 1UK HealthCare, 800 Rose St. H-109, ment of seizures has broadened significantly article is to discuss the past, present and future of Lexington, KY 40536-0293, USA †Author for correspondence: over the past decade [1]. Many of the newer AED pharmacology and mechanisms of action. College of Medicine, Department of anti epileptic drugs (AEDs) have clinical advan- Neurology, University of Kentucky, 800 Rose Street, Room L-455, tages over older, so-called ‘first-generation’ First-generation AEDs Lexington, KY 40536, USA AEDs in that they are more predictable in their Broadly, the mechanisms of action of AEDs can Tel.: +1 859 323 0229 Fax: +1 859 323 5943 dose–response profile and typically are associ- be categorized by their effects on the neuronal [email protected] ated with less drug–drug interactions.
    [Show full text]
  • The International Student Journal of Nurse Anesthesia
    Volume 15 Issue 1 Spring 2016 The International Student Journal of Nurse Anesthesia TOPICS IN THIS ISSUE Ondansetron to prevent SAB-induced Hypotension Hyperthermic Intraperitoneal Chemotherapy Carnitine Palmitoyltransferase Deficiency Adductor Canal vs. Femoral Nerve Block Ketamine Induction for Awake Intubation Airway Management for Tracheostomy TIVA for Gastroenterology Procedures Hematoma Following Thyroidectomy Tranexamic Acid in Trauma Tracheoesophageal Fistula Reintubation in the PACU Venous Air Embolism Emergence Delirium Preventing OR Fires INTERNATIONAL STUDENT JOURNAL OF NURSE ANESTHESIA Vol. 15 No. 1 Spring 2016 Editor Vicki C. Coopmans, CRNA, PhD Associate Editor Julie A. Pearson, CRNA, PhD Editorial Board Laura Ardizzone, CRNA, DNP Memorial Sloan Kettering Cancer Center; NY, NY MAJ Sarah Bellenger, CRNA, MSN, AN Darnall Army Medical Center; Fort Hood, TX Laura S. Bonanno, CRNA, DNP Louisiana State University Health Sciences Center Carrie C. Bowman Dalley, CRNA, MS Georgetown University Marianne Cosgrove, CRNA, DNAP Yale-New Haven Hospital School of Nurse Anesthesia LTC Denise Cotton, CRNA, DNAP, AN Winn Army Community Hospital; Fort Stewart, GA Janet A. Dewan, CRNA, PhD Northeastern University Kären K. Embrey CRNA, EdD University of Southern California Millikin University and Rhonda Gee, CRNA, DNSc Decatur Memorial Hospital Marjorie A. Geisz-Everson CRNA, PhD University of Southern Mississippi Johnnie Holmes, CRNA, PhD Naval Hospital Camp Lejeune Anne Marie Hranchook, CRNA, DNP Oakland University-Beaumont Donna Jasinski,
    [Show full text]